BCMAxCD3 Bispecific Antibody Elranatamab Is Effective in Patient Myeloma Relapsed after BCMA CAR-T

被引：2
|
作者：
Keller, Alana L. [1 ]
Parzych, Sarah E. [1 ]
Reiman, Lauren T. [1 ]
Walker, Zachary J. [1 ]
Forsberg, Peter A. [2 ]
Sherbenou, Daniel W. [1 ]
机构：
[1] Univ Colorado, Div Hematol, Anschutz Med Campus, Aurora, CO USA
[2] Univ Colorado, Div Hematol, Hlth Blood Disorders & Cell Therapies Ctr, Aurora, CO USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187385
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
    Fumou Sun
    Yan Cheng
    Visanu Wanchai
    Wancheng Guo
    David Mery
    Hongwei Xu
    Dongzheng Gai
    Eric Siegel
    Clyde Bailey
    Cody Ashby
    Samer Al Hadidi
    Carolina Schinke
    Sharmilan Thanendrarajan
    Yupo Ma
    Qing Yi
    Robert Z. Orlowski
    Maurizio Zangari
    Frits van Rhee
    Siegfried Janz
    Gail Bishop
    Guido Tricot
    John D. Shaughnessy
    Fenghuang Zhan
    Nature Communications, 15
  • [22] Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma
    Feng, Deming
    Sun, Jian
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (02)
  • [23] Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study
    Li, Chenggong
    Wang, Xindi
    Wu, Zhuolin
    Luo, Wenjing
    Zhang, Yinqiang
    Kang, Yun
    Xu, Jia
    Huang, Zhongpei
    Du, Mengyi
    Tang, Lu
    Wu, Jianghua
    Liao, Danying
    Kou, Haiming
    Lu, Cong
    Jiang, Huiwen
    Wei, Qiuzhe
    Ke, Sha
    Zheng, Jing'e
    Xiong, Wei
    Deng, Jun
    Hu, Yu
    Mei, Heng
    BLOOD, 2022, 140 : 4573 - 4574
  • [24] Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma
    Saldarriaga, Mateo Mejia
    Pan, Darren
    Unkenholz, Caitlin
    Mouhieddine, Tarek H.
    Velez-Hernandez, Juan Esteban
    Engles, Katherine
    Fein, Joshua A.
    Monge, Jorge
    Rosenbaum, Cara
    Pearse, Roger
    Jayabalan, David
    Gordillo, Christian
    Chan, Hei Ton
    Yamshon, Samuel
    Thibaud, Santiago
    Mapara, Markus
    Inghirami, Giorgio
    Lentzsch, Suzanne
    Reshef, Ran
    Rossi, Adriana
    Parekh, Samir
    Jagannath, Sundar
    Richard, Shambavi
    Niesvizky, Ruben
    Bustoros, Mark
    BLOOD ADVANCES, 2024, 8 (15) : 3859 - 3869
  • [25] Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma
    Stefanie Palfi
    Lauren C. Peres
    Himara Koelmeyer
    Melissa Alsina
    Rachid C. Baz
    Brandon J. Blue
    Salvatore Corallo
    Gabriel De Avila
    Ciara Freeman
    Rebecca Gonzalez
    Ariel Grajales-Cruz
    Kristy Harvey
    Hien D. Liu
    Taiga Nishihori
    Guilherme H. Oliveira
    Laura B. Oswald
    Omar Castaneda Puglianini
    Sruthi Selvakumar
    Alexis Behne Sharma
    Elicia Wang
    Kenneth H. Shain
    Michael Jain
    Frederick L. Locke
    Mohammed Alomar
    Doris K. Hansen
    Dae Hyun Lee
    Blood Cancer Journal, 15 (1)
  • [26] An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
    Wang, Qingming
    Wei, Runhong
    Guo, Shufang
    Min, Chao
    Zhong, Xiong
    Huang, Hui
    Cheng, Zhi
    CANCER GENE THERAPY, 2024, 31 (01) : 108 - 118
  • [27] An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
    Qingming Wang
    Runhong Wei
    Shufang Guo
    Chao Min
    Xiong Zhong
    Hui Huang
    Zhi Cheng
    Cancer Gene Therapy, 2024, 31 : 420 - 426
  • [28] Bispecific Antibodies Improve Outcomes in Patients With Relapsed or Refractory Multiple Myeloma After Car-T Cell Therapy
    Merz, Maximilan
    Dima, Danai
    Hashmi, Hamza
    Mueller, Fabian
    Ahmed, Nausheen
    Rathje, Kristin
    Davis, James
    Holderried, Tobias
    Vucinik, Vladan
    Kharbouti, Soraya
    Ayuk, Francis
    Stoelzel, Friedrich
    Schub, Natalie
    Schmitz, Friederike
    Shune, Leyla
    Khouri, Jack
    Anwer, Faiz
    McGuirk, Joseph
    Teichert, Marcel
    von Tresckow, Bastian
    Kroeger, Nicolaus
    Pabst, Thomas
    Abdallah, Al-Ola
    Gagelmann, Nico
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S73 - S74
  • [29] Salvage therapies and clinical outcomes after relapse following BCMA CAR-T in patients with relapsed/refractory multiple myeloma
    Reyes, Kevin
    Liu, Yen-Chun
    Huang, Chiung-Yu
    Banerjee, Rahul
    Martin, Thomas
    Shah, Nina
    Wong, Sandy
    Wolf, Jeffrey
    Arora, Shagun
    Chung, Alfred
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S31 - S32
  • [30] Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
    Bumma, Naresh
    Richter, Joshua
    Brayer, Jason
    Zonder, Jeffrey A.
    Dhodapkar, Madhav
    Shah, Mansi R.
    Hoffman, James E.
    Mawad, Raya
    Maly, Joseph J.
    Lentzsch, Suzanne
    Suvannasankha, Attaya
    Roy, Pourab
    Dey, Jyotirmoy
    Chokshi, Dhruti
    Boyapati, Anita
    Visich, Jenn
    Houvras, Yariv
    Lorenc, Karen Rodriguez
    Kroog, Glenn S.
    Jagannath, Sundar
    BLOOD, 2022, 140 : 10140 - 10141
12345